San Diego, CA (PRWEB) March 23, 2013
Resource4thePeople announced today that its lawyers are still investigating claims from women alleging that they have suffered serious blood-clotting problems as a result of using the popular NuvaRing brand vaginal ring.
The announcement comes as the first bellwether trial selected from more than 1,000 lawsuits* involving claims that the NuvaRing puts women at higher risk of suffering blood clots than other contraceptives approaches in July.
“We have been receiving numerous inquiries from consumers asking whether the approach of a trial in the multi-district litigation affects their ability to file a claim,” said Resource4thePeople.
“The answer is that there is still time for most women who believe they have suffered alleged side effects to contact us and allow us to investigate the facts of their case.
“However, because this is a multi-district litigation that could eventually be designated a class-action case there could be some legal time limits affecting claim so the best way to actually determine eligibility is to contact our attorneys as soon as possible.”
The court records in the NuvaRing multi-district litigation show that the number of cases has increased to 1,097* with the common allegations, according to the court files, involving claims that the NuvaRing puts women at higher risk of suffering a blood clot than with other birth control methods.
For example, said Resource4thePeople, one of the most recent such NuvaRing lawsuits** was filed recently by a Philadelphia woman who claims she suffered a venous sinus thrombosis and an intracranial hemorrhage last year.
In her lawsuit, the woman is claiming that those problems were caused by blood clotting caused by her use of a NuvaRing IUD over seven years.
In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.
Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.
As with the NuvaRing lawsuits in the multidistrict litigation, the Philadelphia woman claims that the defendants were negligent in not fully informing the public and health care professionals about increased risk of blood-clotting from the use of the contraceptive, according to the court filing.
The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.
The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.
This flexibility was one of the marketing factors that made the NuvaRing what was described as an easy and healthy contraceptive choice to women who were not satisfied with the side effects caused by birth control pills and the necessity of taking them each day.
However, by 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.***
Resource4thePeople is committed to informing women about the risks they may face in their choices of contraception and providing them data that ensures the protection of their health and that of any infants they may give birth to who may be exposed to side effects from contraceptive devices.
In announcing that free legal consultations are still being offered to women who may have suffered serious side effects from the use of the NuvaRing, Resource4thePeople notes that NuvaRing has now posted warnings about the increased risks of suffering blood clots on the company’s web site under the heading of “IMPORTANT SAFETY INFORMATION.****
"Our legal consultations can spell out the options available to women who may have suffered health problems from blood clotting, such as deep vein thrombosis, pulmonary embolisms, strokes and heart attacks," said Resource4thePeople.
Legal assistance also is available to those who may have lost a loved one and may be seeking information about the facts involved in a wrongful death.
“This announcement is being made in case there is any confusion among women who might have suffered serious health problems similar to those alleged in what is now a large, consolidated federal court proceeding,” said Resource4thePeople.
Multidistrict litigations are designated by a special panel of federal judges in cases in which large numbers of plaintiffs file similar allegations against common defendants in the interest of judicial efficiency and to avoid duplicative and conflicting legal proceedings.
In such litigations the judge oversees pre-trial evidence-gathering and legal requirements, schedules bellwether cases to allow both plaintiffs and defendants to weigh the strengths and weaknesses of their cases and presides over mediations and settlement discussions.
The judge is also asked to rule on whether such cases should be certified as class-action cases, in which a large pool of plaintiffs are given the choice of whether to remain in the litigation or proceed with their individual case outside of the outcome of the class action.
- In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, U.S. District Court, Eastern District of Missouri
** Case No. 2:13cv0099, U.S. District Court for the Eastern District of Pennsylvania